1RV.F Rhythm Pharmaceuticals Inc

Healthcare Biotechnology Frankfurt Exchange
97.50 EUR
Close of Nov 12, 2026
63.00 101.00
Market cap
EUR 6.76B
P/E
-
P/B
85.86x
ROE
-96.8%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is 1RV.F undervalued?

Graham number

The Graham number of Rhythm Pharmaceuticals Inc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Rhythm Pharmaceuticals Inc fundamental analysis

No fundamental analysis for Rhythm Pharmaceuticals Inc yet.

Rhythm Pharmaceuticals Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Rhythm Pharmaceuticals Inc

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases in the United States and internationally. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, Bardet-Biedl and Alström syndrome, Prader-Willi syndrome, and hypothalamic obesi…

Full company profile